USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, MONOPRIL-HCT should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
Fosinopril is converted to fosinoprilat by hepatic cleavage of the ester group. Fosinoprilat, the active metabolite of fosinopril, is a non-sulfhydryl angiotensin-converting enzyme inhibitor. Hydrochlorothiazide is a diuretic.
MONOPRIL-HCT (fosinopril sodium-hydrochlorothiazide tablets) is indicated for the treatment of hypertension.
These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION.)
In using MONOPRIL-HCT, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema).
Media Articles Related to Monopril-HCT (Fosinopril / Hydrochlorothiazide)
Hypertension in children, teens linked to poorer cognitive skills
Source: Hypertension News From Medical News Today [2016.09.30]
Researchers found that children and adolescents with high blood pressure performed worse on cognitive tests than those with normal blood pressure.
Innovative sound therapy treats hypertension and migraine
Source: Headache / Migraine News From Medical News Today [2016.09.17]
A groundbreaking device that aligns the left and right brain using sound alone may reduce the symptoms of migraine, hypertension, and insomnia.
Hypertension: Releasing the pressure at its source
Source: Hypertension News From Medical News Today [2016.09.07]
Researchers eyeing first new anti-hypertensive drug treatment strategy in more than 15 years.
Source: MedicineNet Cirrhosis Specialty [2016.09.06]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 9/6/2016 12:00:00 AM
New understanding of pulmonary hypertension leads to promising drug targets
Source: Hypertension News From Medical News Today [2016.08.22]
A groundbreaking new study led by researchers from the University of Pittsburgh and UPMC has identified a new group of compounds that could have robust effects in treating pulmonary hypertension...
Page last updated: 2016-09-30